J&J reports Q2
This article was originally published in The Rose Sheet
Executive Summary
Skin care continues to drive performance of firm's consumer business, booking operational growth of 5.9% for fiscal 2009 second quarter. Neutrogena and Aveeno again are standout brands, the latter having launched Nourish+ hair care -- formulated with a wheat protein complex to revitalize damaged hair -- during the quarter (1"The Rose Sheet" March 2, 2009). Firm's U.S. skin-care sales advanced 8.4% operationally, while international sales were up 3.8% partly on strength of products acquired last year from Chinese brand Dabao (2"The Rose Sheet" Aug. 4, 2008, In Brief). Oral-care revenue was down 5.9% in the U.S. due to "softness in the category," but increased 9.5% abroad on an operational basis, with Listerine leading the charge. Overall consumer sales declined 4.5% to $3.9 bil. in what CFO Dominic Caruso calls "one of the most challenging quarters for year-over-year comparisons in [firm's] history" owing to tighter consumer spending, stiffer private-label competition and the loss of market exclusivity as patents expired for J&J drugs including Risperdal and Topomax. However, based on recent launches, approvals and filings with FDA, firm says it has "one of the most robust pharmaceutical pipelines in [its] history." Total company sales in Q2 were $15.2 bil. worldwide, down 7.4%, on a reported basis
You may also be interested in...
Aveeno’s Premier Hair-Care Range Builds Upon Skin-Care Equity
Aveeno is looking to capitalize on its reputation for natural-based skin care products with the launch of Aveeno Nourish+, its first hair-care line, which contains a wheat protein to revive damaged hair
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.